Biasco Luca, Pellin Danilo, Scala Serena, Dionisio Francesca, Basso-Ricci Luca, Leonardelli Lorena, Scaramuzza Samantha, Baricordi Cristina, Ferrua Francesca, Cicalese Maria Pia, Giannelli Stefania, Neduva Victor, Dow David J, Schmidt Manfred, Von Kalle Christof, Roncarolo Maria Grazia, Ciceri Fabio, Vicard Paola, Wit Ernst, Di Serio Clelia, Naldini Luigi, Aiuti Alessandro
San Raffaele Telethon Institute for Gene Therapy (TIGET), 20132 Milan, Italy.
CUSSB, Vita-Salute University, 20132 Milan, Italy.
Cell Stem Cell. 2016 Jul 7;19(1):107-19. doi: 10.1016/j.stem.2016.04.016. Epub 2016 May 26.
Hematopoietic stem/progenitor cells (HSPCs) are capable of supporting the lifelong production of blood cells exerting a wide spectrum of functions. Lentiviral vector HSPC gene therapy generates a human hematopoietic system stably marked at the clonal level by vector integration sites (ISs). Using IS analysis, we longitudinally tracked >89,000 clones from 15 distinct bone marrow and peripheral blood lineages purified up to 4 years after transplant in four Wiskott-Aldrich syndrome patients treated with HSPC gene therapy. We measured at the clonal level repopulating waves, populations' sizes and dynamics, activity of distinct HSPC subtypes, contribution of various progenitor classes during the early and late post-transplant phases, and hierarchical relationships among lineages. We discovered that in-vitro-manipulated HSPCs retain the ability to return to latency after transplant and can be physiologically reactivated, sustaining a stable hematopoietic output. This study constitutes in vivo comprehensive tracking in humans of hematopoietic clonal dynamics during the early and late post-transplant phases.
造血干细胞/祖细胞(HSPCs)能够支持终身血细胞生成,发挥广泛的功能。慢病毒载体HSPC基因治疗可产生一个在克隆水平上由载体整合位点(ISs)稳定标记的人类造血系统。通过IS分析,我们纵向追踪了4例接受HSPC基因治疗的威斯科特-奥尔德里奇综合征患者移植后长达4年的15种不同骨髓和外周血谱系中超过89,000个克隆。我们在克隆水平上测量了再增殖波、群体大小和动态、不同HSPC亚型的活性、移植后早期和晚期不同祖细胞类别的贡献以及谱系之间的层级关系。我们发现,体外操作的HSPCs在移植后保留了恢复到潜伏期的能力,并且可以被生理激活,维持稳定的造血输出。这项研究构成了对人类移植后早期和晚期造血克隆动态的体内全面追踪。